• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    State Street SPDR S&P Biotech ETF (NY:XBI)

    126.35 -2.18 (-1.70%)
    Streaming Delayed Price Updated: 12:05 PM EST, Jan 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about State Street SPDR S&P Biotech ETF

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    News headline image
    RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
    REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases. 
    Via Stocktwits
    News headline image
    Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
    The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
    Via Stocktwits
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
    Via Stocktwits
    IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
    Via Stocktwits
    Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
    Via Stocktwits
    IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
    Via Stocktwits
    News headline image
    Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
    The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
    Via Stocktwits
    Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
    Via Stocktwits
    IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
    Via Stocktwits
    News headline image
    Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
    Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
    Via Stocktwits
    News headline image
    Healthcare Sector Falters: S&P 500's Biggest Loser Amid Broader Market Caution
    New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index... 
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral ↗
    Via Stocktwits
    White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
    Via Stocktwits
    News headline image
    Eaton, FTAI Aviation And More On CNBC&#39;s &#39;Final Trades&#39; ↗
    FTAI Aviation (NASDAQ: FTAI) is recommended by investment experts to diversify portfolios beyond tech, while Eaton (NYSE: ETN) and SPDR S&P Biotech ETF (NYSE: XBI) show promising price action. SoFi's... 
    Via Benzinga
    Topics ETFs Stocks
    News headline image
    Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. ↗
    The SPDR S&P Biotech ETF is a compelling investment option. 
    Via The Motley Fool
    Topics ETFs Economy Government
    News headline image
    Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off ↗
    Rotating To Healthcare Please click here for an enlarged chart comparing Invesco QQQ Trust Series 1 (NASDAQ: 
    Via Benzinga
    Topics Economy
    News headline image
    Taiwan Semiconductor, HealthEquity, Cboe Global Markets And More: CNBC's 'Final Trades' ↗
    Stephen Weiss of Short Hills Capital Partners, named Taiwan Semiconductor Manufacturing Company as his final trade. 
    Via Benzinga
    News headline image
    Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗
    Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
    Via Benzinga
    Topics ETFs
    News headline image
    FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
    Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science. 
    Via Stocktwits
    Topics Lawsuit
    News headline image
    Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin ↗
    As markets enter their strongest stretch, ETFs tied to AI, banking, and healthcare could shine. Here's where investors are finding fresh momentum. 
    Via Benzinga
    Topics Artificial Intelligence ETFs
    News headline image
    Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
    Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
    Via Benzinga
    News headline image
    Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗
    Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
    Via Stocktwits
    News headline image
    Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
    The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
    SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
    Via Benzinga
    News headline image
    4 Biotech Stocks Seeing Explosive Momentum Gains ↗
    The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
    Via Benzinga
    Topics ETFs Stocks
    News headline image
    How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline ↗
    Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
    Via Benzinga
    Topics ETFs Government
    News headline image
    SciSparc And AutoMax Call Off Merger ↗
    SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
    Via Benzinga
    Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma ↗
    Via Stocktwits
    Topics Government
    News headline image
    Pharma Tariffs Back In Spotlight On New Trump Threat ↗
    President Donald Trump threatened 100% tariffs on some drug imports. 
    Via Investor's Business Daily
    Topics ETFs Government World Trade
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.